For inhibitors of the m6A-recognition protein, a compound called “7,773” has been found to bind IGF2BP1 and inhibit its interaction with KRAS RNA (139), thereby reducing the expression of KRAS protein and downstream signaling, inhibiting the cancer-promoting activity of IGF2BP1. The gene discussed is KRAS; the disease is cancer.